Insulin-like growth factor hypoglycemia

Injectable recombinant human insulin-like growth factor (rhIGF-I rINN mecasermin) has been available for nearly 20 years for treatment of the rare instances of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies. It has also been used as an insulin-sensitizing agent in severe insulin-resistant conditions. Adverse reactions to mecasermin have been reviewed [24 ]. The most common adverse reaction is hypoglycemia, which is readily controlled by administration with meals. 

---